Profile
Jennifer Champoux is the Chief Operating Officer of Monte Rosa Therapeutics, Inc. (GLUE), as disclosed in the company's SEC filing dated January 5, 2026. Monte Rosa Therapeutics is a biotechnology company focused on molecular glue degraders and utilizes the QuEEN platform to identify target proteins for degradation. In her COO role, she leads day-to-day operations and strategic execution, with the filing noting no stock purchases or sales by her in the period covered.
| Role | Insider |
|---|
| Notability | 42/100 |
|---|
Board memberships
- Monte Rosa Therapeutics, Inc.
Awards & honors
- Oversees operational functions for a clinical-stage biotech focused on molecular glue degraders
- Drives corporate strategy, finance operations, and development operations aligned with Monte Rosa's pipeline
- Contributes to expansion of the QuEEN platform capabilities and related operations
Frequently Asked Questions
Who is Champoux Jennifer?
Jennifer Champoux is the Chief Operating Officer of Monte Rosa Therapeutics, Inc. (GLUE), as disclosed in the company's SEC filing dated January 5, 2026. Monte Rosa Therapeutics is a biotechnology company focused on molecular glue degraders and utilizes the QuEEN platform to identify target proteins for degradation. In her COO role, she leads day-to-day operations and strategic…
How many SEC Form 4 filings has Champoux Jennifer submitted recently?
4 primary Form 4 filings in the last 90 days, covering 1 company.
Has Champoux Jennifer been buying or selling stock?
Recorded transactions: 0 open-market purchases () and 5 open-market sales ($210K) across all tracked filings.
Where can I see all of Champoux Jennifer's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.